Johnson & Johnson Acquired in-process research and development decreased by 95.5% to $16.00M in Q3 2025 compared to the prior quarter.
High spending indicates a strong commitment to pipeline growth, though it carries significant execution and regulatory risk.
This represents the cash outflow for the acquisition of in-process research and development projects from other entities...
High in the pharmaceutical industry where external innovation is a primary driver of long-term revenue.
cf_acquired_ipr_d| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $117.50M | $117.50M | $117.50M | $117.50M | $0.00 | $0.00 | $14.00M | $355.00M | $16.00M |
| QoQ Change | — | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | — | >999% | -95.5% |
| YoY Change | — | — | — | — | — | — | — | — | -100.0% | -100.0% | — | — | — |
We use cookies for analytics. See our Privacy and Cookie Policy.